stockrow
Friday 6 November 2026
Export SYBX’s income statement to Excel — free account
Synlogic, Inc.
SYBX Healthcare Biotechnology
Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023.
- EPS
- 0.00%
- Free cash flow
- −277.9%
Quarter to June 2026, against a year earlier
1.10
0.10
+10.00%
Follow SYBX
Alert me
Synlogic, Inc. (SYBX) P/E ratio
Synlogic, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 6.1× (June 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
Low 0.0×
High 6.1×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPRX Kiora Pharmaceuticals, Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| IMRN IMMURON compare | n/m |
| ENVB Enveric Biosciences, Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| SYBX Synlogic, Inc. | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)